Extensive phenotyping of vascular damage in non-infectious primary vasculitides with the use of non-invasive vascular biomarkers: prevalence, pathogenesis and response to treatment

Ouralia Agryropoulou, Athanase Protogerou, Antonis Argyris, Athanasios Tzioufas, Panayiotis Vlachoyiannopoulos

Mediterr J Rheumatol 2018;29(3):173-7
Extensive phenotyping of vascular damage in non-infectious primary vasculitides with the use of non-invasive vascular biomarkers: prevalence, pathogenesis and response to treatment

Ournia Agryropoulou, Athanase Protogerou, Antonis Argyris, Athanasios Tzioufas, Panayiotis Vlachoyiannopoulos

Department of Pathophysiology, “Laiko” Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

INTRODUCTION

Non-Infectious Primary Systemic Vasculitides (NIPSV) is a heterogeneous group of rare and potentially life-threatening diseases characterized by inflammation of the vascular wall. The size and localization of the involved vessels in association with the nature of the inflammatory process (focal or systemic, presence of necrosis, immune complex formation) account for the variability of the clinical manifestations between the various NIPSV. Prior to the introduction of corticosteroids, the natural history of untreated NIPSV was that of a rapidly progressive and
usually fatal disease. Nowadays, the causes of death include cancer and infections due to chronic immune activation and/or to immunosuppressive therapy. Vascular complications (involving both micro- and macro-circulation) are major sources of morbidity and mortality in NIPSV. Microvascular complications are major causes of premature deaths especially in small vessel vasculitides: they affect predominantly the kidney (acute renal failure) and the lung (pulmonary hemorrhage). Macrovascular complications (e.g., coronary artery disease, stroke, aneurysm formation and rupture) are major causes of morbidity and mortality especially in medium and large vessel vasculitides. Lumen stenosis, occlusion or aneurysmal dilatation of blood vessels due to intramural inflammation and necrosis represent the major vascular pathology in NIPSV. Mural fibrin deposition in arterioles or venules, as well as angiogenic inflammatory cell infiltration are the hallmarks of biopsy-proven diagnosis. The early steps in the immunological process of vascular damage in NIPSV cannot be considered to be uniform, since various discrete mechanisms such as endothelial activation and dysfunction, autoantibodies to endothelial cell-surface antigens or neutrophil components and abnormal IgA tissue deposition are involved. Beyond the NIPSV specific pathways of vascular damage, numerous evidence suggests that the classical pathways of arterial damage, namely, atheromatosis (i.e., atheromatic plaque formation), inappropriate arterial remodeling (e.g., arterial hypertrophy / distention) and arteriosclerosis (i.e., arterial stiffening), are accelerated, thus participating in the development of micro- and macro-vascular complications in NIPSV. In brief, the main related mechanisms involve: (i) the primary intramural vessel wall inflammation; (ii) the secondary vessel wall inflammation due to systemic inflammation; (iii) NIPSV-related drug treatment induced deleterious effects on the vessel wall; and (iv) the effect of classical cardiovascular disease risk factors. However, numerous unanswered questions exist due to the limited number of NIPSV patients and methodological limitations (lack of prospective data, often misused interpretation of vascular biomarkers) that reduce the value of many published studies. Strong data on the acceleration of vascular damage (atheromatosis and increased arterial stiffening) are currently present in Takayasu Arteritis, Kawasaki Disease and Behcet’s Disease. The association of atheromatosis and arteriosclerosis with PN and small vessel vasculitides remains the less established, so far. The actual contribution of classical vascular pathology in the development of morbidity and mortality in NIPSV is not known. The effect of anti-inflammatory drugs on the function and structure of the large and small arteries has not known. The effect of anti-inflammatory treatment from disease onset with disease activity in NIPSV; and (v) to study the effect of anti-inflammatory treatment from disease onset (or relapse) to complete remission and follow-up. To test the previously described hypothesis of biphasic effect of corticosteroids on the function and structure of the large and small arteries, Secondary aims: (i) to identify the prevalence of classical cardiovascular diseases risk factors (hypertension, dyslipidemia, smoking, diabetes) in NIPSV, using state-of-the-art methodology (e.g., out-of-office blood pressure monitoring); (ii) Explorative & hypothesis generating analysis: DNA and miRNA will be extracted to stored. NIPSV considered as prototype of high grade vascular wall inflammation with extreme flares and periods of complete remission, will be used as a model to perform exploratory analysis leading to novel hypothesis regarding the molecular pathogenesis vascular disease linked to inflammation. Future perspectives (in a separate 2nd phase study): In a future follow-up study of the present cohort, we will evaluate the prognostic value of these biomarkers to predict morbidity and mortality and to be used as valid biomarkers to guide diagnosis and response to treatment.

METHODS
Prospective observational study; anticipated study duration (based on 6 month pilot study is calculated around 3 years (2018-2021); sample size: 200 (25 per disease group at least) patients and 400 age- and gender-matched individuals without chronic inflammatory disease, NSIP or history of neoplastic disease who will serve as controls. Baseline and follow-up vascular evaluation of all the participants will be performed in pre-defined visits on the basis of disease activity, remission and relapse, as defined. Baseline and follow-up vascular evaluation of all the participants will be performed in pre-defined visits on the basis of disease activity, remission and relapse, as defined by international guidelines per disease (Table 1). Patients with any type of NIPSV - diagnosed on the basis of classical international criteria per disease - fulfilling the inclusion criteria will be recruited in one of the following 3
groups: Group A: consecutive newly diagnosed patient with NIPSV; Group B: NIPSV with active relapse; Group C: consecutive NIPSV patients in steady disease - remission status for at least 3 months with steady medication. Age- and gender-matched individuals without any chronic inflammatory disease and NIPSV will serve as control group. Extensive vascular studies with high resolution ultrasound, oscillometry and tonometry will be performed at the carotid bed, the femoral bed, the aorta, the upper arm and lower limbs and retina in order to evaluate atherosclerosis, arteriosclerosis/elasticity, arterial remodeling and hypertrophy endothelial function, wave reflections and aortic hemodynamics, retinal geometry ([Table 2](#)) in 2 to 5 sequential visits within 6-9 months (visit 0, visit 1=1 week, visit 2= 1 month, visit 3= 3 months, visit 4 ≥ 6 months) in each patient starting from disease onset/relapse to complete remission. Anthropometric parameters, dietary habits, lipids and other blood samples, DNA, RNA, urine samples, tissues biopsies, PET/CT will be recorded in predefined visits.

Patients involved in the study are informed in detail and give written consent. All data are collected under code in anonymous electronic files, in which only researchers have access, at the Cardiovascular Prevention & Research Unit of the Department of Pathophysiology of Medical School of National & Kapodistrian University of Athens. Under the above particular circumstances, biological materials; blood serum, DNA, RNA and biopsy tissues are collected and retained anonymous at the biobank of cells and tissues of the Department of Pathophysiology of Medical School of National & Kapodistrian University of Athens. Ethical approval has been obtained.

---

**Table 1: Study flow chart**

| Visit | Hospitalized | Duration | Anticipated disease status | NIPSV-Related treatment | Cardiovascular treatment | Vascular tests | PET/CT* | Blood tests** | Biopsies |
|-------|-------------|----------|---------------------------|-------------------------|--------------------------|---------------|---------|--------------|---------|
| 0     | yes         | 0        | Active Disease (newly diagnosed or disease relapse) | Naive or steady for months | Naive or steady | Steady if possible | x       | x            | x       | If possible |
| 1     | yes         | <7 days  | Still active disease (newly diagnosed or relapse) | 1-2 just after IV high dose completion therapy | 1-2 days after 1st dose | Steady if possible | x       | +/-          | x       |
| 2     | no          | 1st month | «Start» of remission | Just before dose tapering | Steady if possible | Steady if possible | x       | x            |
| 3     | no          | 3rd month | Remission | Tapering completion (start of minimal dose or no dose) | Steady if possible | Steady if possible | x       | x            |
| 4     | no          | 6th month | Remission | Steady | Steady if possible | Steady if possible | x       | x            |

**Legend**

- Visit 0 for newly diagnosed patient (group A); visit 1 for disease relapse (group B); visit 3 for patient in steady disease remission status for at least 3 months with steady drugs (group C).
- * PET/CT will be performed at the Biomedical Research Foundation Academy of Athens (BRFAA) only for visits 0 or 1 and to verify complete disease remission (visit 4).
- ** Renal function, metabolic profile, inflammation profile and disease specific test if need will be performed.

Serum from all visits will be stored anonymous at the biobank of cells and tissues of the Department of Pathophysiology of Medical School of National & Kapodistrian University of Athens.
by the Bioethics and Ethics Committee of National and Kapodistrian University of Athens.

**Statistical analysis**

Statistical analysis will be performed by SPSS v. 23.0 using appropriate test per hypothesis and populations. The data will be analyzed and presented in the overall population as well per disease and disease status, after normal distribution control. Comparison of the outcome variables (vascular indices) between and within groups will be performed before and after adjusting for potential confounders using independent multiple t-tests, ANOVA, paired t-test, linear and logistic regression analysis, and chi-square tests as appropriate. Receiver operator curve analysis will be performed to identify ability of the outcome variables to detect disease activity. Sensitivity and mediation analysis will be performed.

**ANTICIPATED BENEFITS:**
- To optimize the understanding of vascular pathology in NIPSV.
- To identify potential useful easy to measure non-invasive vascular tools for diagnosis and follow-up of NIPSV patients.
To generate hypothesis regarding the molecular basis of association of inflammation with classical vascular pathology (atheromatosis, arteriolosclerosis, arterial remodeling).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Elefante E, Tripoli A, Ferro F, Baldini C. One year in review: systemic vasculitis. Clin Exp Rheumatol. 2016;34(Suppl.97):S1-S6. [PMID: 27214397]
2. Nelson S S, Pande S, Kushwah A P S. A study of atherosclerosis in Systemic vasculitis. Int J Sci Stud 2014;2:25-9.
3. Eleftheriadis E, Eleftheriadis N. Coronary Artery Disease and Systemic Vasculitides: Case report and Review. Coronary Artery Diseases, edited by Dr Illya Chakovsky. INTECH 2012;13:281-300. [http://doi.org/10.5772/30544]
4. Adebajo A, Dickson D J. Collected reports on the Rheumatic Diseases 2005 series 4 (revised) Primary Systemic Vasculitis. Arthritis Research Campaign (arc) 2005;70-1.
5. Savage C O, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997;349:553-8. [PMID: 9048802]
6. Kernani T, Warrington K, Amin S. Malignancy risk in vasculitis. Ther Adv Musculoskeletal Dis 2011;3(1):55-63. [https://doi.org/10.1177/1759720X10387460] [PMID: 22870466]
7. Hong J, Marson D, Shirai T, Weyand C. Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumatol 2015;10(6):365-81. [PMID: 27042216]
8. Shirwany N A, Zou M-H. Arterial stiffness: a brief review. Acta Pharmacol Sin 2010;31:1267-76. [http://doi.org/10.1038/aps.2010.123] [PMID: 20802505]
9. Argyropoulou O D, Protogerou A D, Sifakis P P. Accelerated atheromatosis and arteriosclerosis in primary systemic vasculitides: current evidence and future perspectives. Curr Opin Rheumatol 2018;30(1):36-43. [https://doi.org/10.1097/BOR.0000000000000453] [PMID: 29040156]